In Top Ten No. (5) Life Techs. v. Promega Corp., the Court GRANTED certiorari, but only as to the Second Question Presented, which asks whether supplying a single, commodity component of a multi-component invention from the United States is an infringing act under 35 U.S.C. § 271(f)(1).
In Top Ten No. (2) Sequenom v. Ariosa Diagnostics, the Court DENIED certiorari in this case that involves patent-eligibility under 35 USC § 101 of a claimed method to determine the presence in a blood sample of a known substance (here, DNA) where that substance,as such, is known and not in any event patent-eligible.
A further explanation of the cases is found in the attached Top Ten Patent Cases.
Regards,
Hal